Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With RDS

NCT02482766 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2019-02-15

No results posted yet for this study

Summary

The primary hypothesis of this study is reduction in need of mechanical ventilation in the first 72 hours of life (excluding the transient tracheal intubation performed for surfactant administration and the mechanical ventilation for lung recruitment) in spontaneously breathing infants born at 24+0-27+6 weeks' gestation and failing nCPAP during the first 24 hours of life who received an HFOV recruitment maneuver (IN-REC-SUR-E) compared to no recruitment maneuver (IN-SUR-E) just prior to surfactant administration followed by prompt extubation.

Conditions

  • Respiratory Distress Syndrome
  • Hyaline Membrane Disease

Interventions

DRUG

Poractant alfa, 200 mg/kg

Endotracheal Surfactant administration

DEVICE

Ventilator for High-frequency Oscillatory Ventilation (HFOV)

This device will be used to perform an HFOV recruitment maneuver before surfactant administration

DEVICE

Nasal Continuous Positive Airway Pressure (nCPAP)

After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)

Sponsors & Collaborators

  • Ospedali Riuniti Ancona

    collaborator OTHER
  • Careggi Hospital

    collaborator OTHER
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    collaborator OTHER
  • Centre for Neonatal Research and Education, Crawley, West Australia

    collaborator UNKNOWN
  • Monash University

    collaborator OTHER
  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER
  • Catholic University of the Sacred Heart

    lead OTHER

Principal Investigators

  • Giovanni Vento, MD · Catholic University of the Sacred Heart

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
24 Weeks
Max Age
27 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02482766 on ClinicalTrials.gov